30,000
25,000
20,000
15,000
10,000
5,000
0
16,918
FY 18
22,792
FY 19
25,986
FY 20
Revenue
30%
25%
20%
15%
10%
5%
0%
16.5%
FY 18
16.8%
FY 19
20.2%
FY 20
EBITDA %
6,000
5,000
4,000
3,000
2,000
1,000
0
2,784
FY 18
3,840
FY 19
5,253
FY 20
EBITDA
4,200
3,500
2,800
2,100
1,400
7,00
0
1,326
FY 18
2,364
FY 19
3,355
FY 20
PAT
18%
15%
12%
9%
6%
3%
0%
7.8%
FY 18
10.4%
FY 19
12.9%
FY 20
PAT%
24,000
20,000
16,000
12,000
8,000
4,000
0
13,042
FY 18
15,295
FY 19
18,437
FY 20
Networth
24,000
20,000
16,000
12,000
8,000
4,000
0
11,996
FY 18
14,729
FY 19
18,752
FY 20
Gross Block
Break-up of Consolidated Revenue as per Geography
FY'20 (Rs. in Mn)13,879
53%
5,055
19%
2,100
8%
3,795
15%
1,157
4%
North America
Europe
India
Latin America
Row
Break-up of Consolidated Revenue as per Business Segment
FY'20 (Rs. in Mn)13,602
52%
8,170
31%
4,214
16%
API
PFI
FD
Break-up of Consolidated Revenue as per Molecule
FY'20 (Rs. in Mn)7,487
29%
6,011
23%
6,397
25%
733
3%
1,374
5%
3,985
15%
Paracetamol
Metformin
Guaifenesin
Ibuprofen
Methocarbamol
Others
Break-up of Consolidated Revenue as per Business Segment
FY'20 (Rs. in Mn)13,602
52%
8,170
31%
4,214
16%
API
PFI
FD
